Retatrutide vs Liraglutide (Saxenda): A Comparison

Overview

Liraglutide (sold as Saxenda for weight management and Victoza for type 2 diabetes) and retatrutide come from two very different generations of incretin-based drugs. Liraglutide was the first GLP-1 receptor agonist approved specifically for obesity, gaining FDA approval in 2014. Retatrutide is one of the newest molecules in development: a triple GIP/GLP-1/glucagon receptor agonist now in Phase 3 trials through Eli Lilly’s TRIUMPH program.

Putting the two side by side shows how far weight-loss drugs have come in just over a decade. Liraglutide was seen as a breakthrough when it launched. Retatrutide’s trial data are on a different scale altogether.

Important note: No trial has compared retatrutide with liraglutide directly. Every efficacy comparison here is cross-trial and affected by differences in study design, patient populations, trial length and how outcomes were measured.

Key Differences at a Glance

Mechanism of Action

Liraglutide (Saxenda)

Liraglutide is a GLP-1 analogue with 97% structural similarity to natural human GLP-1. It works only through the GLP-1 receptor:

• Appetite regulation: Activating GLP-1 receptors in the hypothalamus reduces hunger and increases fullness
• Delayed gastric emptying: Slows stomach emptying, so you stay full longer after meals
• Glucose-dependent insulin secretion: Boosts insulin release when blood glucose is high
• Glucagon suppression: Lowers glucagon secretion, so the liver releases less glucose

At the 3.0 mg Saxenda dose (higher than the 1.8 mg Victoza dose used for diabetes), these effects are tuned for weight management. Even so, liraglutide engages only one of the three receptor systems retatrutide targets.

Retatrutide

Retatrutide activates three receptor systems at once, which gives it a much broader effect:

• GLP-1 receptor: Appetite suppression and glucose control (shared with liraglutide)
• GIP receptor: Better fat tissue function, extra insulin secretion, and early evidence of action on appetite centers in the brain
• Glucagon receptor: Direct fat burning in the liver, higher energy use and heat production. Liraglutide has none of these effects

The key difference: liraglutide works mainly by cutting energy intake, while retatrutide both cuts intake and raises energy use. Working on both sides of energy balance creates a much larger calorie deficit, and the weight loss data reflect that.

Weight Loss Comparison

The efficacy gap between these two drugs is one of the largest among obesity medicines.

Liraglutide (Saxenda)

The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trials established liraglutide 3.0 mg as an effective obesity treatment:

• Mean weight loss: About 8% of body weight at 56 weeks in the SCALE Obesity and Prediabetes trial
• Categorical thresholds: About 63% of participants lost at least 5%; about 33% lost at least 10%
• When SCALE was published, these results were considered clinically meaningful, and they are. An 8% weight loss brings real improvements in metabolic risk factors, blood pressure and quality of life

Retatrutide

Retatrutide’s Phase 3 TRIUMPH-4 trial reported very different numbers:

• Mean weight loss: 28.7% at the 12 mg dose over 68 weeks
• Categorical thresholds: 58.6% of participants lost at least 25%; 39.4% lost at least 30%
• The weight loss curve had not fully flattened at 68 weeks, which suggests more loss with continued treatment

The Scale of the Difference

Across trials, retatrutide produced about 3.5 times the weight loss of liraglutide. In absolute terms, for a person weighing 110 kg (243 lbs) at baseline, liraglutide would be expected to take off roughly 9 kg (20 lbs), while retatrutide took off roughly 32 kg (70 lbs) at the 12 mg dose.

The gap reflects the difference between working on energy balance through one receptor and through three. Liraglutide was the best drug available when it launched. The field has moved a long way since.

Dosing and Administration

Here retatrutide has a clear practical advantage.

Liraglutide (Saxenda)

Saxenda is a daily subcutaneous injection, taken at any time of day, with or without meals. The dose increases as follows:

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onward: 3.0 mg daily (maintenance dose)

The daily injection is Saxenda’s biggest practical burden. Many people find it hard to keep up a daily injection for months and years, especially compared with weekly options. Missed doses, travel and injection fatigue all make real-world adherence harder.

Retatrutide

Retatrutide is a once-weekly subcutaneous injection. In clinical trials, the dose started at 2 mg and stepped up every 4 weeks to a target of 9 mg or 12 mg. The escalation is slower than Saxenda’s because it has to work across three receptor targets while keeping GI side effects manageable.

Weekly dosing is a real quality-of-life advantage. Once-weekly GLP-1 drugs (semaglutide, tirzepatide) have consistently shown better real-world adherence than daily ones, and the same would be expected for retatrutide.

Side Effects Comparison

Both drugs’ main side effects are the GI effects typical of GLP-1 drugs, but at different rates:

A few points stand out:

GI rates are broadly similar. Saxenda at its top dose already causes substantial GI side effects. Retatrutide’s rates are somewhat higher, but the difference is much smaller than the efficacy gap.

Injection site reactions were noticeably more common with Saxenda than with most weekly injectables, probably because of the daily injections and injection volume.

Dysesthesia is the biggest difference. TRIUMPH-4 reported dysesthesia (tingling, numbness or burning, usually in the hands and feet) in 20.9% of the 12 mg retatrutide group versus 0.7% on placebo. It has not been seen with liraglutide or any other approved GLP-1 receptor agonist. It was mostly mild and rarely led people to stop treatment, but it is a genuinely new safety finding that needs monitoring. See our detailed analysis of the dysesthesia signal for more.

Long-Term Safety

Saxenda has more than a decade of post-marketing safety data. Millions of people worldwide have used liraglutide, and its safety profile is well understood. Known long-term issues include a low rate of gallbladder events (as with weight loss from any cause), the GLP-1 class warning on thyroid C-cell tumors (based on rodent studies, with uncertain relevance to people) and rare reports of pancreatitis.

Retatrutide’s safety profile rests entirely on clinical trials with thousands of participants over up to 68 weeks. The long-term effects of activating three receptors for years, and especially of constant glucagon receptor activation, still have to be established through longer treatment and post-marketing surveillance.

Cardiovascular Evidence

Liraglutide

The LEADER trial showed that liraglutide (at the 1.8 mg diabetes dose) cut major adverse cardiovascular events (MACE) by 13% in people with type 2 diabetes and high cardiovascular risk. That trial used the Victoza dose rather than the Saxenda dose, but it offers some cardiovascular reassurance for the molecule.

Retatrutide

There are no cardiovascular outcomes data for retatrutide. The TRIUMPH-Outcomes trial is running to measure cardiovascular and kidney outcomes, but results are years away. Phase 2 showed improvements in cardiovascular risk factors (blood pressure, lipids, inflammatory markers), but these are surrogate markers, not hard outcomes.

Liver Fat Reduction

Here retatrutide’s triple mechanism produces a different kind of result.

Liraglutide lowers liver fat modestly, mostly as a side effect of weight loss. Some studies have shown liver fat reductions of 30-40% with liraglutide, driven by better insulin sensitivity and less visceral fat.

In Phase 2a MASLD data, retatrutide 12 mg cut liver fat by about 82% in relative terms, and 86% of participants reached normal liver fat (below 5%) at 24 weeks. Its glucagon component drives fat burning in the liver directly, a liver-specific effect liraglutide lacks.

Availability and Practical Considerations

Saxenda (Available Now)

• FDA-approved since December 2014 for chronic weight management
• Available in most countries worldwide
• Brand Saxenda list price $1,349 per month in the United States (NovoCare); the first generic, from Teva, launched in August 2025
• Insurance coverage varies; some plans cover it for obesity, many do not
• Requires daily cold-chain storage (refrigeration)
• Doctors know how to prescribe it and have long experience with it

Retatrutide (Investigational)

• Not approved for any indication
• Available only through clinical trial enrollment
• Application planned no later than Q1 2027 (the FDA says it must be an NDA, which Lilly is contesting: see the FDA ruling); earliest FDA approval late 2027, base case first half of 2028
• Commercial pricing not established (Eli Lilly launched Zepbound at a list price of about $1,060/month in 2023, a rough reference point)
• No compounding or off-label access pathway exists

Who Would Consider Switching

For many patients the real question is whether to stay on Saxenda or wait for newer drugs. A few situations are worth thinking through:

If you have not reached your goals on Saxenda, you are the most likely candidate for a newer drug. If 8% weight loss is not enough for your needs, whether for metabolic health, mobility, sleep apnea or quality of life, the much greater efficacy of retatrutide (or of drugs available now, such as tirzepatide) may be worth it.

If you are doing well on Saxenda, there is less reason to switch. If your weight loss meets your goals and you tolerate the drug well, the value of a familiar, well-understood treatment should not be underestimated.

If daily injections frustrate you, a once-weekly drug may appeal. You can get that now with approved weekly options (semaglutide or tirzepatide) without waiting for retatrutide.

Timing matters. Retatrutide is not available today and will not be for at least one to two years. If your situation needs action now, work with your doctor on the options available today rather than waiting for a drug still finishing its trials.

Frequently Asked Questions

Is retatrutide better than Saxenda?

Cross-trial data strongly suggest retatrutide produces far more weight loss than liraglutide: about 28.7% versus 8% at top doses. Weekly dosing is also easier than Saxenda’s daily injections. On the other hand, Saxenda has more than a decade of real-world safety data, is available now, and is well established with insurers and prescribers. Whether retatrutide is “better” depends on your goals, your tolerance for risk and your timeline. No head-to-head trial has been done.

When will retatrutide replace Saxenda?

Retatrutide is not expected to win FDA approval until late 2027 at the earliest. Even then, Saxenda is unlikely to disappear. Some patients respond well to it, and its long safety record has value. Still, obesity medicine is moving toward more effective drugs, and Saxenda’s market share has already fallen since semaglutide (Wegovy) and tirzepatide (Zepbound) arrived. Retatrutide would probably speed that up.

Can I switch from Saxenda to retatrutide?

Not yet, because retatrutide is only available in clinical trials. If it is approved, switching guidance would need to be developed. Both drugs are injected under the skin, but retatrutide’s dose escalation would probably start from the beginning whatever your Saxenda dose. Any switch would need to be managed by a doctor.

Does retatrutide have worse side effects than Saxenda?

GI side effect rates are broadly similar at top doses. The most notable difference is dysesthesia with retatrutide (20.9% at 12 mg), which has not been seen with Saxenda. In trials it was mostly mild and went away on its own. Saxenda’s daily injections also cause more injection site reactions than weekly injectables usually do.

Is Saxenda still worth taking in 2026?

Saxenda is still an FDA-approved, effective obesity treatment that produces clinically meaningful weight loss. But it is no longer the most effective option. Semaglutide (Wegovy) and tirzepatide (Zepbound) both produce more weight loss with weekly dosing and are available now. If you are on Saxenda and not meeting your goals, talk to your doctor about the alternatives available today. You do not necessarily need to wait for retatrutide.

Why is the weight loss difference so large?

The roughly 3.5-fold difference comes down to pharmacology. Liraglutide works through one receptor (GLP-1), mainly to reduce appetite. Retatrutide works through three receptors to reduce appetite (GLP-1 and GIP) and raise energy use (glucagon). Eating less while burning more creates a much larger energy deficit. A decade of drug development separates the two molecules, and the efficacy gap reflects what researchers learned about metabolism in that time.